Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Ocugen, Inc.NASDAQ: OCGN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $8.12M rose 25.8% year over year, ahead of the +9.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 32.4% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.
Context
- Selling, general & admin amounted to 624.9% of revenue in FY2025, down 33.2 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $37.83M (+37.2%) for the fiscal year ending Dec 2026, a step up from the +3.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.12M+32.4% QoQ
- Last fiscal yearDec 2025
- $27.58M+3.3% YoY
- LTMMar 2026
- $29.24M+9.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 27.58M USD
- Year-over-year change
- +3.3%
- 4-year CAGR
- +4.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.58M | +3.3% |
| FY2024 | 2024-12-31 | 26.69M | -16.6% |
| FY2023 | 2023-12-31 | 31.99M | -9.6% |
| FY2022 | 2022-12-31 | 35.4M | +54.5% |
| FY2021 | 2021-12-31 | 22.92M | — |
Selling, General & Admin vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 selling, general & admin of $29.24M is the 7th highest of the 10 companies compared; the peer median is $33.4M.
- Its year-over-year change of +9.4% is the 4th highest of 10, against a peer median of +3.6%.
- Selling, general & admin amounts to 654.9% of revenue for OCGN, versus a peer median of 126.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $82.03M | +32.5% | — | 103.6% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M | +17.2% | +94.2% | 1041.9% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $34.94M | -61.3% | — | 50.2% | |
| LTM Mar 2026 | $33.4M | -31.3% | -6.4% | 337.6% | |
| LTM Mar 2026 | $29.77M | -10.8% | -11.7% | — | |
| LTM Mar 2026 | $29.24M | +9.4% | -8.0% | 654.9% | |
| LTM Mar 2026 | $27.57M | +8.0% | +40.7% | — | |
| LTM Mar 2026 | $18.69M | +3.6% | -6.4% | 126.4% | |
| LTM Mar 2026 | $18.51M | +10.2% | +13.1% | — | |
| Peer median (excluding OCGN) | $33.4M | +3.6% | +13.1% | 126.4% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.49M | 6.04M | 4.06M | 4.41M |
| Cost of Revenue | 0 | 0 | 704K | 1.97M | 2.39M |
| Gross Profit | 0 | 2.49M | 5.33M | 2.09M | 2.02M |
| Gross Margin | — | 100.0% | 88.3% | 51.5% | 45.9% |
| Research & Development | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| Selling, General & Admin | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| Operating Expenses | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| EBITDA | (58.11M) | (86.32M) | (62.37M) | (52.09M) | (60.27M) |
| EBITDA Margin | — | -3469.6% | -1033.4% | -1284.5% | -1365.7% |
| Operating Income | (58.03M) | (89.07M) | (65.53M) | (54.76M) | (62.92M) |
| Operating Margin | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Interest Income | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 79K | 0 | 0 | 0 | 5.19M |
| Other Income / Expenses | (389K) | 2.27M | 2.45M | 703K | (4.93M) |
| Income Before Tax | (58.42M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Pre-Tax Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| Income Tax Expense | (52K) | 0 | 0 | 0 | 0 |
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Net Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (Basic) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| EPS (Diluted) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| Weighted Avg Shares | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Weighted Avg Shares (Diluted) | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.